Biomarin’s hemophilia drug nets PRIME status in Europe
BioMarin Pharmaceutical’s treatment for hemophilia has been accepted for PRIME (Priority Medicines) scheme from the European Medicines Agency (EMA).
Pharmaceuticals, Biotechnology and Life Sciences
BioMarin Pharmaceutical’s treatment for hemophilia has been accepted for PRIME (Priority Medicines) scheme from the European Medicines Agency (EMA).
Achaogen’s multi-drug resistant (MDR) gram-negative product antibiotic candidate, plazomicin, met the objective for the U.S. Food and Drug Administration (FDA)…
European Commission (EC) has granted an additional indication for Novartis’s Lucentis (ranibizumab) to treat patients with eye disease due to…
European Patent Office has granted ValiRx’s patent covering its major therapeutic compound VAL201, including prostate cancer, the pharmaceutical company said on…
GeNeuro and Servierhave set up a study they named ANGEL-MS, which is a long-term extension study for patients with multiple sclerosis…